Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Price Target of $5.46

Key Points

• Analysts hold a mixed view of Cellectis, with two sell, two hold, two buy and one strong-buy rating, resulting in a consensus “Hold” and an average 12-month price target of $5.46.
• Recent analyst actions were largely cautious: Wells Fargo, Robert W. Baird and Barclays lowered their price targets, with Barclays downgrading the stock to “underweight” and cutting its target to $1.30.
• CLLS opened at $1.47, well below its 50-day and 200-day moving averages, while the company reported a quarterly loss of $0.22 per share—better than expected—but revenue of $6.9 million missed consensus estimates.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) has received an average rating of "Hold" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $5.46.

A number of equities analysts have issued reports on the company. Wells Fargo & Company cut their price target on Cellectis from $4.00 to $3.00 and set an "equal weight" rating for the company in a research note on Tuesday, September 15th. Citizens Jmp reissued a "market perform" rating on shares of Cellectis in a research report on Tuesday, September 15th. Weiss Ratings downgraded Cellectis from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, September 16th. Robert W. Baird cut their price target on shares of Cellectis from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Tuesday, September 15th. Finally, Barclays lowered Cellectis from an "overweight" rating to an "underweight" rating and reduced their price objective for the company from $9.00 to $1.30 in a report on Wednesday, September 16th.

Hedge Funds Weigh In On Cellectis

An institutional investor recently bought a new stake in Cellectis stock. Lido Advisors LLC acquired a new stake in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 10,094 shares of the biotechnology company's stock, valued at approximately $32,000. Hedge funds and other institutional investors own 63.90% of the company's stock.

Cellectis Price Performance

CLLS stock opened at $1.47 on Wednesday. The company's 50-day moving average is $2.70 and its 200-day moving average is $3.16. The stock has a market capitalization of $147.50 million, a PE ratio of -2.26 and a beta of 2.92. The company has a debt-to-equity ratio of 1.61, a current ratio of 1.37 and a quick ratio of 1.37. Cellectis has a 1 year low of $1.25 and a 1 year high of $5.48.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04. The firm had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Cellectis Company Profile

Cellectis SA NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis' product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.